AVANT Immunotherapeutics Inc. develops vaccines and targeted immunotherapeutics for the treatment of cancer, infectious and inflammatory diseases. It focuses on the use of tumor-specific targets and human monoclonal antibodies to precisely deliver therapeutic agents through its novel “targeted immunization” approach. It has three commercialized products, including Rotarix® for the prevention of rotavirus infection, and two human food safety vaccines for reducing salmonella infection in chickens and eggs.